Drugs / SRP-6004
SRP-6004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05906251 | May 2023 → Jun 2025 | limb-girdle muscular dystrophy | Sarepta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRP-6004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05906251 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “rAAVrh74.MHCK7.DYSF.DV” NCT05906251 ↗ |
| Route | Intravenous | “Single IV infusion of SRP-6004” NCT05906251 ↗ |
| Target | DYSF | “rAAVrh74.MHCK7.DYSF.DV” NCT05906251 ↗ |